Annual Health Insurance Treatment Cost of Female Infertility of Another Origin Based on Routinely Collected Financing Data between 2010-2019
Author(s)
Pónusz-Kovács D1, Bódis J2, Csákvári T3, Elmer D4, Kajos L1, Pónusz R1, Kovács B5, Kovács KA2, Boncz I2
1University of Pécs, Pécs, BA, Hungary, 2University of Pécs, Pécs, Hungary, 3University of Pécs Faculty of Health Sciences, Zalaegerszeg, ZA, Hungary, 4University of Pécs, Pécs, PE, Hungary, 5University of Pécs, BUDAPEST, PE, Hungary
OBJECTIVES: Female infertility is a global health problem affecting approximately 120 million women worldwide. Female infertility constitutes a significant and growing burden on patients, health care systems and the society. Our aim was to determine the annual costs of the health insurance system related to the female infertility in Hungary between 2010 and 2019.
METHODS: Data were derived from the financial database of the National Health Insurance Fund Administration of Hungary, of the year 2010 and 2019. Data analyzed included annual health insurance costs, numbers of patient and cost distribution calculated for age groups. The following cost categories were included into the study: general practice care, home care, in- and outpatient care, laboratory diagnostics and pharmaceuticals. Patients with female infertility of another origin were identified with the following code of the International Classification of Diseases 10th revision: N97.8.
RESULTS: In 2019, the Hungarian National Health Insurance Fund Administration spent 2.6 million USD on the health care treatment of patients with female infertility, which is higher than in 2010 (829,3 thousand USD). The costs of inpatient care (2010: 37.2%; 2019: 52.4%) and pharmaceuticals (2010: 38.9%; 2019: 43.4%) were the main cost drivers from the annual health care expenditure in the analyzed years. Annual health care treatment cost per a patient was 1,496 USD in 2010 and 3.340 USD in 2019 in inpatient care. The highest annual health insurance costs were found in ‘30-39’ and ‘40-49’ age groups in 2010, while in 2019 costs of ’30-39’ and ’40-49’ age groups increased almost to same level.
CONCLUSIONS: In 2019 the utilization of treatment with female infertility of other origin was 3.4 times higher than in 2010. The largest increase of health insurance costs were found in the treatment of ’40-49’ age group (2.9 times), especially in inpatient, pharmaceuticals and outpatient care.
Conference/Value in Health Info
Value in Health, Volume 27, Issue 6, S1 (June 2024)
Code
RWD10
Topic
Economic Evaluation, Health Policy & Regulatory, Real World Data & Information Systems
Topic Subcategory
Health & Insurance Records Systems, Insurance Systems & National Health Care
Disease
Reproductive & Sexual Health